{
    "clinical_study": {
        "@rank": "147867", 
        "acronym": "EBI", 
        "arm_group": [
            {
                "arm_group_label": "EBI-005-2 5mg/ml", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration: 3 times per day"
            }, 
            {
                "arm_group_label": "EBI-005-2 20 mg/ml", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration: 3 times per day"
            }, 
            {
                "arm_group_label": "EBI-005-2 Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administration: 3 times per day"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1b, multi-center, double-masked, randomized, placebo-controlled,\n      parallel-group study designed to evaluate the safety and biological activity of two doses of\n      EBI-005 ophthalmic solution versus placebo in subjects with moderate to severe Dry Eye\n      Syndrome. Approximately 72 subjects will be enrolled and randomized in this study at up to 9\n      centers located in the United States (US). Subjects will be enrolled in two groups or\n      cohorts. The first enrollment group will consist of 33 subjects."
        }, 
        "brief_title": "A Multi-Center Study Subjects With Dry Eye Syndrome", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  To investigate the safety and tolerability of EBI-005 ophthalmic solution compared to\n           placebo in the treatment of patients with moderate to severe Dry Eye Syndrome (DES).\n\n        -  To evaluate pharmacokinetic (PK) parameters and immunogenicity of two different doses\n           of EBI-005 ophthalmic solution.\n\n        -  To investigate the biological activity of multiple doses of EBI-005 ophthalmic solution\n           compared to placebo as assessed by both objective and subjective assessments.\n\n        -  To investigate the comparative dose response of two different doses of EBI-005\n           ophthalmic solution.\n\n        -  To investigate the comparative tolerability of two different doses of EBI-005\n           ophthalmic solution.\n\n        -  To identify key biomarkers in the diagnosis and management of subjects with DES."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide written informed consent prior to any study related procedures\n\n          -  Are 18 years of age or older\n\n          -  Are women of child bearing potential (WOCBP) who are non-pregnant, non-lactating and\n             sexually inactive (abstinent) for 14 days prior to Visit 1\n\n          -  Are willing and able to follow instructions and can be present for the required study\n             visits for the duration of the study\n\n          -  Have a history of Dry Eye Syndrome in both eyes supported by a previous clinical\n             diagnosis\n\n          -  Have ongoing Dry Eye Syndrome, in the same eye or both eyes, as defined by the\n             following criteria:\n\n               1. A score of \u226523 on OSDI\n\n               2. A corneal fluorescein staining score of \u22656 (NEI scale)\n\n          -  Have normal lid anatomy\n\n          -  Are willing to withhold artificial tears for the duration of the study, with the\n             exception of the study provided artificial tears: Refresh Plus\u00ae.\n\n        Exclusion Criteria: Subjects may not:\n\n          -  Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept or Ilaris).\n\n          -  Have an OSDI score \u226590\n\n          -  Have a corneal fluorescein staining score of 15 (NEI scale). NOTE: If one of two eyes\n             has a corneal fluorescein staining score of 15, the subject may be eligible.\n\n          -  Within 30 days prior to the screening visit (Visit 1) have taken: Topical\n             cyclosporine (Restasis\u00ae) Ocular corticosteroids Autologous serum Topical ocular\n             antibiotics Topical ocular antihistamines or mast cell stabilizers Topical or nasal\n             vasoconstrictors\n\n          -  Within 30 days prior to the screening visit (Visit 1) have altered the dose of\n             tetracycline compounds (tetracycline, doxycycline or minocycline)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745887", 
            "org_study_id": "EBI-005-2"
        }, 
        "intervention": {
            "arm_group_label": [
                "EBI-005-2 5mg/ml", 
                "EBI-005-2 20 mg/ml"
            ], 
            "description": "The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.", 
            "intervention_name": "EBI-005-2", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Dry Eye Syndrome", 
            "Interleukin 1 Receptor Inhibitor"
        ], 
        "lastchanged_date": "August 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Artesia", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90701"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ranchero Cordova", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95670"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrence", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90505"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63090"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44115"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78209"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome", 
        "other_outcome": {
            "measure": "Gene transcription levels measured from cells collected via impression cytology", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "overall_official": {
            "affiliation": "Eleven Biotherapeutics", 
            "last_name": "Michael Goldstein, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "OSDI is a subject assessment tool to determine subject Dry Eye Syndrome symptoms", 
            "measure": "OSDI (Ocular Surface Disease Index)", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Corneal staining assessment will be performed using methods developed by the NEI Dry Eye Workshop.", 
                "measure": "Change from baseline in total corneal fluorescein staining", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Patient Reported Outcome using a Visual Analog Scale for Modified SANDE.", 
                "measure": "Symptom Assessment in Dry Eye (Modified SANDE)", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Eleven Biotherapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eleven Biotherapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}